224436-97-9

Basic information

• Product Name: 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine
• Synonyms: 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine;2-ThiazolaMine, 5-[[[5-(1,1-diMethylethyl)-2-oxazolyl]Methyl]thio]-;2-aMino-5-[[[5-(1,1-diMethylethyl)-2-oxazolyl]Methyl]thio]-thiazole;5-(((5-(tert-Butyl)oxazol-2-yl)methyl)thio)thiazol-2-amine
• CAS NO: 224436-97-9
• Molecular Formula: C₁₁H₁₅N₃OS₂
• Molecular Weight: 269.3863
• Mol File: 224436-97-9.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 412.051 °C at 760 mmHg
• Flash Point: 203.001 °C
• Appearance: /
• Density: 1.297 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.615
• CAS DataBase Reference: 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine(224436-97-9)
• EPA Substance Registry System: 5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-amine(224436-97-9)

Safety Data

• Hazardous Substances Data: 224436-97-9(Hazardous Substances Data)

Usage

Description

5-[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl-1,3-thiazol-2-amine is a complex organic chemical compound that is part of the thiazole and oxazole derivatives family. It features a sulfanyl-substituted thiazole and oxazol structure, with a 1,3-thiazol-2-amine group. 5-[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl-1,3-thiazol-2-amine is defined by its molecular formula C11H16N4OS2 and has a molecular weight of 288.4 g/mol. Its potential applications, particularly in the pharmaceutical sector, are of interest, although further research is necessary to fully understand its properties and uses.

Uses

Used in Pharmaceutical Industry:
5-[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl-1,3-thiazol-2-amine is used as a potential active pharmaceutical ingredient for the development of new drugs. Its unique structure may offer specific binding affinities or interactions with biological targets, which could be leveraged for therapeutic purposes. However, the exact mechanisms of action and the scope of its applications within this industry are still under investigation.
Given the current information, the specific applications and reasons for using 5-[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl-1,3-thiazol-2-amine in other industries are not detailed in the provided materials. Further research would be required to explore its potential uses in areas such as materials science, agrochemicals, or other specialized fields.

InChI:InChI=1/C11H15N3OS2/c1-11(2,3)7-4-13-8(15-7)6-16-9-5-14-10(12)17-9/h4-5H,6H2,1-3H3,(H2,12,14)

Upstream product

• 61296-22-8 5-bromothiazol-2-amine hydrobromide 
• 2472-88-0 tetrabutylammonium sulfate 
• 23056-10-2 2-amino-5-thiocyanatothiazole 
• 1334492-54-4 2-(bromomethyl)-5-(tert-butyl)oxazole 
• 13547-70-1 1-chloro-3,3-dimethyl-butan-2-one 
• 33124-07-1 5-tert-butyl-oxazol-2-ylamine 
• 224441-73-0 2-(chloromethyl)-5-t-butyloxazole 
• 3282-30-2 pivaloyl chloride 
• 6832-15-1 1-diazo-3,3-dimethyl-2-butanone 
• 333389-44-9 α-N-2-(chloroacetylamino)pinacolone 
• 33119-72-1 1-amino-3,3-dimethylbutan-2-one hydrochloride 
• 5469-26-1 1-Bromopinacolon 
• 76779-98-1 1-azido-3,3-dimethyl-2-butanone 
• 224435-04-5 N-[5-[[(5-t-butyl-2-oxazolyl)methyl]thio]-2-thiazolyl]acetamide 

Downstream Products

• 333389-46-1 4-(bromomethyl)-N-[5-[[[5-tert-butyl-2-oxazolyl]methyl]thio]-2-thiazolyl]benzeneacetamide 
• 333389-48-3 N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-3-formylbenzeneacetamide 
• 1093252-80-2 C₁₇H₂₅N₃OS₂ 

Relevant articles and documents

INHIBITORS OF CYCLIN-DEPENDENT KINASES

The present invention provides novel compounds of Formulae (I'), (I), (II'), and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK7, CDK12, or CDK13), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

CDK INHIBITORS

The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer.

N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl] -4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent

N-Acyl-2-aminothiazoles with nonaromatic acyl side chains containing a basic amine were found to be potent, selective inhibitors of CDK2/cycE which exhibit antitumor activity in mice. In particular, compound 21 {N-[5-[[[5-(1,1-dimethylethyl)-2- oxazolyl]m